Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Lux Research Announces First Quarter Update of Lux Nanotech Index™

Lux Research Announces First Quarter Update of Lux Nanotech Index™

Lux Research

New York, NY | Posted on April 03, 2006

Lux Research, the world’s leading nanotechnology research and advisory firm, today announced its quarterly update to the Lux Nanotech Index™. The Index serves as a benchmark for the value that markets ascribe to emerging nanotechnology and forms the basis of the $93 million PowerShares Lux Nanotech Portfolio (AMEX:PXN), the first nanotechnology exchange-traded fund (ETF).

The components of the Lux Nanotech Index™ are split into two groups: 1) nanotech specialists – small and mid-sized companies that focus specifically on developing or funding emerging nanotechnology applications, and 2) end-use incumbents – large companies that are applying nanotechnology to existing product lines. Nanotech specialists account for 75% of the modified equal-dollar-weighted index; end-use incumbents account for 25%.

This update replaces Westaim with NUCRYST Pharmaceuticals among the nanotech specialists. NUCRYST, which develops therapeutic applications of silver nanoparticles, was a business unit of Westaim before it was spun off in a late December 2005 IPO; with the spinoff, Westaim’s nanotech commercialization activities have been divested. “The Acticoat antimicrobial bandages that NUCRYST developed with partner Smith & Nephew form a great example of how nanotechnology is changing products and shifting market shares today,” said Lux Research President and Director of Research Matthew M. Nordan.

The PowerShares Lux Nanotech Portfolio, which is based on the Index, is up 19.90% since its introduction in October 2005 and now has more than $93 million in assets under management. The Lux Nanotech Index™ is intended to be representative, and is not specifically designed to outperform the Nasdaq or other indices.

The components of the Lux Nanotech Index™ are:

Nanotech specialists

  • Accelrys (ACCL)
  • Altair Nanotechnologies (ALTI)
  • American Pharmaceutical Partners (APPX)
  • Arrowhead Research (ARWR)
  • Biosante Pharmaceuticals (BPA)
  • Elan (ELN)
  • FEI Company (FEIC)
  • Flamel Technologies (FLML)
  • Headwaters (HW)
  • Immunicon (IMMC)
  • Nanophase Technologies (NANX)
  • NUCRYST Pharmaceuticals (NCST)
  • NVE Corporation (NVEC)
  • Cambridge Display Technology (OLED)
  • Symyx Technologies (SMMX)
  • Harris & Harris Group (TINY)
  • Veeco Instruments (VECO)

End-use incumbents

  • Air Products & Chemicals (APD)
  • BASF (BF)
  • E.I. Du Pont de Nemours & Company (DD)
  • General Electric (GE)
  • Hewlett-Packard (HPQ)
  • Intel (INTC)
  • International Business Machines (IBM)
  • 3M (MMM)
  • Toyota (TM)

Full details on the Lux Nanotech Index™ are available at www.luxresearchinc.com/luxni.html.

####

About Lux Research:
Lux Research is the world’s leading nanotechnology research and advisory firm. We help our clients make better decisions to profit from nanoscale science and technology, tapping into our analysts’ unique expertise and unrivaled network. Our clients include top decision makers at large corporations, portfolio managers and analysts at leading financial institutions, CEOs of the most innovative start-ups, and visionary public policy makers.

For more information, please click here.

Contact:
Lux Research Inc.
Peter Hebert
646-723-0702
peter.hebert@luxresearchinc.com

Copyright © Lux Research

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Daikin Industries becomes OCSiAl shareholder July 27th, 2021

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

Announcements

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project